DaVita (DVA) Competitors

$201.41 +2.48 (+1.25%)

As of 02:59 PM Eastern

DVA vs. ALGN, DXCM, HQY, MMSI, and CAH

Should you buy DaVita stock or one of its competitors? MarketBeat compares DaVita with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with DaVita include Align Technology (ALGN), DexCom (DXCM), HealthEquity (HQY), Merit Medical Systems (MMSI), and Cardinal Health (CAH). These companies are all part of the "medical" sector.

How does DaVita compare to Align Technology?

Align Technology (NASDAQ:ALGN) and DaVita (NYSE:DVA) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

DaVita has higher revenue and earnings than Align Technology. DaVita is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Align Technology	$4.03B	2.98	$410.35M	$5.96	28.13
DaVita	$13.64B	0.95	$746.80M	$10.78	18.71

Align Technology presently has a consensus price target of $205.85, suggesting a potential upside of 22.78%. DaVita has a consensus price target of $199.17, suggesting a potential downside of 1.27%. Given Align Technology's stronger consensus rating and higher probable upside, research analysts plainly believe Align Technology is more favorable than DaVita.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Align Technology	0 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.57
DaVita	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.38

88.4% of Align Technology shares are owned by institutional investors. Comparatively, 90.1% of DaVita shares are owned by institutional investors. 0.8% of Align Technology shares are owned by insiders. Comparatively, 1.5% of DaVita shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Align Technology has a beta of 1.7, indicating that its stock price is 70% more volatile than the broader market. Comparatively, DaVita has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

Align Technology has a net margin of 10.50% compared to DaVita's net margin of 5.65%. Align Technology's return on equity of 15.82% beat DaVita's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Align Technology	10.50%	15.82%	10.17%
DaVita	5.65%	-270.37%	4.87%

In the previous week, DaVita had 29 more articles in the media than Align Technology. MarketBeat recorded 39 mentions for DaVita and 10 mentions for Align Technology. Align Technology's average media sentiment score of 1.21 beat DaVita's score of 0.79 indicating that Align Technology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Align Technology	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive
DaVita	14 Very Positive mention(s)	3 Positive mention(s)	14 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Align Technology beats DaVita on 10 of the 17 factors compared between the two stocks.

How does DaVita compare to DexCom?

DexCom (NASDAQ:DXCM) and DaVita (NYSE:DVA) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

DexCom has higher earnings, but lower revenue than DaVita. DaVita is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DexCom	$4.66B	5.06	$836.30M	$2.34	26.12
DaVita	$13.64B	0.95	$746.80M	$10.78	18.71

DexCom presently has a consensus price target of $83.22, suggesting a potential upside of 36.16%. DaVita has a consensus price target of $199.17, suggesting a potential downside of 1.27%. Given DexCom's stronger consensus rating and higher probable upside, research analysts plainly believe DexCom is more favorable than DaVita.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DexCom	1 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88
DaVita	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.38

97.8% of DexCom shares are owned by institutional investors. Comparatively, 90.1% of DaVita shares are owned by institutional investors. 0.3% of DexCom shares are owned by insiders. Comparatively, 1.5% of DaVita shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

DexCom has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, DaVita has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

DexCom has a net margin of 19.31% compared to DaVita's net margin of 5.65%. DexCom's return on equity of 33.33% beat DaVita's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DexCom	19.31%	33.33%	13.19%
DaVita	5.65%	-270.37%	4.87%

In the previous week, DaVita had 17 more articles in the media than DexCom. MarketBeat recorded 39 mentions for DaVita and 22 mentions for DexCom. DexCom's average media sentiment score of 1.13 beat DaVita's score of 0.79 indicating that DexCom is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DexCom	13 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
DaVita	14 Very Positive mention(s)	3 Positive mention(s)	14 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

DexCom beats DaVita on 13 of the 17 factors compared between the two stocks.

How does DaVita compare to HealthEquity?

HealthEquity (NASDAQ:HQY) and DaVita (NYSE:DVA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

DaVita has higher revenue and earnings than HealthEquity. DaVita is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HealthEquity	$1.31B	5.21	$215.20M	$2.46	32.92
DaVita	$13.64B	0.95	$746.80M	$10.78	18.71

HealthEquity has a net margin of 16.39% compared to DaVita's net margin of 5.65%. HealthEquity's return on equity of 13.86% beat DaVita's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HealthEquity	16.39%	13.86%	8.67%
DaVita	5.65%	-270.37%	4.87%

99.6% of HealthEquity shares are held by institutional investors. Comparatively, 90.1% of DaVita shares are held by institutional investors. 1.5% of HealthEquity shares are held by company insiders. Comparatively, 1.5% of DaVita shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

HealthEquity has a beta of 0.19, indicating that its stock price is 81% less volatile than the broader market. Comparatively, DaVita has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

In the previous week, DaVita had 30 more articles in the media than HealthEquity. MarketBeat recorded 39 mentions for DaVita and 9 mentions for HealthEquity. HealthEquity's average media sentiment score of 1.26 beat DaVita's score of 0.79 indicating that HealthEquity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HealthEquity	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DaVita	14 Very Positive mention(s)	3 Positive mention(s)	14 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

HealthEquity currently has a consensus price target of $111.79, suggesting a potential upside of 38.03%. DaVita has a consensus price target of $199.17, suggesting a potential downside of 1.27%. Given HealthEquity's stronger consensus rating and higher probable upside, equities analysts plainly believe HealthEquity is more favorable than DaVita.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HealthEquity	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
DaVita	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.38

Summary

HealthEquity beats DaVita on 10 of the 15 factors compared between the two stocks.

How does DaVita compare to Merit Medical Systems?

Merit Medical Systems (NASDAQ:MMSI) and DaVita (NYSE:DVA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

Merit Medical Systems currently has a consensus price target of $92.80, suggesting a potential upside of 51.26%. DaVita has a consensus price target of $199.17, suggesting a potential downside of 1.27%. Given Merit Medical Systems' stronger consensus rating and higher probable upside, equities analysts plainly believe Merit Medical Systems is more favorable than DaVita.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Merit Medical Systems	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
DaVita	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.38

Merit Medical Systems has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market. Comparatively, DaVita has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

DaVita has higher revenue and earnings than Merit Medical Systems. DaVita is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Merit Medical Systems	$1.52B	2.41	$128.49M	$2.31	26.56
DaVita	$13.64B	0.95	$746.80M	$10.78	18.71

Merit Medical Systems has a net margin of 9.03% compared to DaVita's net margin of 5.65%. Merit Medical Systems' return on equity of 13.54% beat DaVita's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Merit Medical Systems	9.03%	13.54%	7.94%
DaVita	5.65%	-270.37%	4.87%

In the previous week, DaVita had 28 more articles in the media than Merit Medical Systems. MarketBeat recorded 39 mentions for DaVita and 11 mentions for Merit Medical Systems. Merit Medical Systems' average media sentiment score of 1.07 beat DaVita's score of 0.79 indicating that Merit Medical Systems is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Merit Medical Systems	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DaVita	14 Very Positive mention(s)	3 Positive mention(s)	14 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

99.7% of Merit Medical Systems shares are held by institutional investors. Comparatively, 90.1% of DaVita shares are held by institutional investors. 0.7% of Merit Medical Systems shares are held by company insiders. Comparatively, 1.5% of DaVita shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Merit Medical Systems beats DaVita on 10 of the 17 factors compared between the two stocks.

How does DaVita compare to Cardinal Health?

DaVita (NYSE:DVA) and Cardinal Health (NYSE:CAH) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

DaVita currently has a consensus price target of $199.17, suggesting a potential downside of 1.27%. Cardinal Health has a consensus price target of $241.80, suggesting a potential upside of 31.23%. Given Cardinal Health's stronger consensus rating and higher possible upside, analysts clearly believe Cardinal Health is more favorable than DaVita.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DaVita	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.38
Cardinal Health	0 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.94

DaVita has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market. Comparatively, Cardinal Health has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market.

Cardinal Health has higher revenue and earnings than DaVita. DaVita is trading at a lower price-to-earnings ratio than Cardinal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DaVita	$13.64B	0.95	$746.80M	$10.78	18.71
Cardinal Health	$222.58B	0.19	$1.56B	$6.54	28.17

DaVita has a net margin of 5.65% compared to Cardinal Health's net margin of 0.62%. Cardinal Health's return on equity of -92.61% beat DaVita's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DaVita	5.65%	-270.37%	4.87%
Cardinal Health	0.62%	-92.61%	4.46%

In the previous week, DaVita had 20 more articles in the media than Cardinal Health. MarketBeat recorded 39 mentions for DaVita and 19 mentions for Cardinal Health. Cardinal Health's average media sentiment score of 1.01 beat DaVita's score of 0.79 indicating that Cardinal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DaVita	14 Very Positive mention(s)	3 Positive mention(s)	14 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Cardinal Health	12 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

90.1% of DaVita shares are held by institutional investors. Comparatively, 87.2% of Cardinal Health shares are held by institutional investors. 1.5% of DaVita shares are held by company insiders. Comparatively, 0.1% of Cardinal Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

DaVita and Cardinal Health tied by winning 8 of the 16 factors compared between the two stocks.

Get DaVita News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DVA vs. The Competition

Export

Metric	DaVita	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$12.95B	$5.65B	$6.28B	$22.92B
Dividend Yield	N/A	1.56%	2.78%	4.03%
P/E Ratio	18.71	34.14	20.55	28.72
Price / Sales	0.95	22.20	545.88	104.53
Price / Cash	9.15	16.51	27.81	19.21
Price / Book	-38.13	3.10	9.62	4.63
Net Income	$746.80M	$218.81M	$3.55B	$1.07B
7 Day Performance	28.51%	1.20%	-0.36%	-0.58%
1 Month Performance	34.59%	4.82%	5.99%	3.47%
1 Year Performance	39.81%	18.82%	38.59%	24.66%

DaVita Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DVA DaVita	3.2808 of 5 stars	$201.73 +1.4%	$199.17 -1.3%	+38.5%	$12.95B	$13.64B	18.71	78,000	Trending News Earnings Report Analyst Forecast Insider Trade
ALGN Align Technology	4.2387 of 5 stars	$171.88 -3.9%	$205.85 +19.8%	-9.5%	$12.81B	$4.03B	28.84	20,290	Positive News
DXCM DexCom	4.828 of 5 stars	$60.04 -2.1%	$83.50 +39.1%	-29.9%	$23.67B	$4.66B	25.66	11,000	Positive News Analyst Downgrade
HQY HealthEquity	4.1833 of 5 stars	$82.18 -0.3%	$111.79 +36.0%	-9.7%	$6.96B	$1.31B	33.41	2,814	Positive News Analyst Downgrade
MMSI Merit Medical Systems	4.1089 of 5 stars	$62.01 flat	$92.80 +49.7%	-37.1%	$3.70B	$1.52B	26.84	7,500	Positive News Insider Trade High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:DVA) was last updated on 5/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DaVita (DVA) Competitors

DVA vs. ALGN, DXCM, HQY, MMSI, and CAH

How does DaVita compare to Align Technology?

Summary

How does DaVita compare to DexCom?

Summary

How does DaVita compare to HealthEquity?

Summary

How does DaVita compare to Merit Medical Systems?

Summary

How does DaVita compare to Cardinal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DVA vs. The Competition

DaVita Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

DaVita (DVA) Competitors

DVA vs. ALGN, DXCM, HQY, MMSI, and CAH

How does DaVita compare to Align Technology?

Which has higher earnings & valuation, ALGN or DVA?

Do analysts rate ALGN or DVA?

Do insiders and institutionals have more ownership in ALGN or DVA?

Which has more volatility and risk, ALGN or DVA?

Is ALGN or DVA more profitable?

Does the media prefer ALGN or DVA?

Summary

How does DaVita compare to DexCom?

Which has higher earnings & valuation, DXCM or DVA?

Do analysts rate DXCM or DVA?

Do insiders and institutionals have more ownership in DXCM or DVA?

Which has more volatility and risk, DXCM or DVA?

Is DXCM or DVA more profitable?

Does the media prefer DXCM or DVA?

Summary

How does DaVita compare to HealthEquity?

Which has better earnings & valuation, HQY or DVA?

Is HQY or DVA more profitable?

Do insiders & institutionals have more ownership in HQY or DVA?

Which has more volatility and risk, HQY or DVA?

Does the media favor HQY or DVA?

Do analysts prefer HQY or DVA?

Summary

How does DaVita compare to Merit Medical Systems?

Do analysts prefer MMSI or DVA?

Which has more volatility and risk, MMSI or DVA?

Which has better earnings & valuation, MMSI or DVA?

Is MMSI or DVA more profitable?

Does the media favor MMSI or DVA?

Do insiders & institutionals have more ownership in MMSI or DVA?

Summary

How does DaVita compare to Cardinal Health?

Do analysts prefer DVA or CAH?

Which has more risk and volatility, DVA or CAH?

Which has preferable earnings and valuation, DVA or CAH?

Is DVA or CAH more profitable?

Does the media refer more to DVA or CAH?

Do insiders & institutionals have more ownership in DVA or CAH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DVA vs. The Competition

DaVita Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools